<DOC>
	<DOCNO>NCT01636505</DOCNO>
	<brief_summary>The aim study perform randomize control trial evaluate rate genetic chromosomal abnormality embryos obtain GnRH-agonist long GnRH-antagonist ovarian stimulation protocol . Patients prospectively randomize two group : first undergo control ovarian stimulation GnRH-agonist long protocol second follow GnRH-antagonist ovarian stimulation regimen . The end-points study include number genetically chromosomally abnormal embryo , pregnancy , implantation healthy baby birth rate . The patient include PGS program select base advance maternal age , repeat pregnancy lose implantation failure whereas patient know carry sex-linked monogenic disorder consider PGD strategy . The uterine abnormality , endometriosis endocrinal disease consider exclusion factor .</brief_summary>
	<brief_title>The Results Preimplantation Genetic Diagnosis Preimplantation Genetic Screening Embryos Obtained From GnRH-agonist Long GnRH-antagonist Ovarian Stimulation Protocol</brief_title>
	<detailed_description />
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>patient carrier genetic disease advance maternal Age repeat IVF failure recurrent pregnancy loss uterine abnormality endometriosis endocrinal disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>